1. Home
  2. MLP vs CAPR Comparison

MLP vs CAPR Comparison

Compare MLP & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MLP

Maui Land & Pineapple Company Inc.

HOLD

Current Price

$16.82

Market Cap

333.8M

Sector

Finance

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$27.94

Market Cap

324.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLP
CAPR
Founded
1909
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
333.8M
324.6M
IPO Year
1972
N/A

Fundamental Metrics

Financial Performance
Metric
MLP
CAPR
Price
$16.82
$27.94
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$41.38
AVG Volume (30 Days)
43.2K
5.9M
Earning Date
11-14-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$18,344,000.00
$11,130,509.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7,736.03
P/E Ratio
N/A
N/A
Revenue Growth
73.55
N/A
52 Week Low
$13.84
$4.30
52 Week High
$23.41
$40.37

Technical Indicators

Market Signals
Indicator
MLP
CAPR
Relative Strength Index (RSI) 60.05 72.77
Support Level $16.52 $25.60
Resistance Level $17.46 $27.18
Average True Range (ATR) 0.58 3.49
MACD 0.06 0.20
Stochastic Oscillator 65.84 63.37

Price Performance

Historical Comparison
MLP
CAPR

About MLP Maui Land & Pineapple Company Inc.

Maui Land & Pineapple Co Inc is a landholding and operating company. ML&P owns, develops, sells, and manages residential, resort, commercial, agricultural, and industrial real estate. It operates in three segments: Land Development & Sales which includes land planning and entitlement, development, and sales activities; Leasing operations include residential, resort, commercial, agricultural, industrial land and property leases; and Resort Amenities segment, which include a membership program that provides certain benefits and privileges within the Kapalua Resort for its members. The majority of its revenue is derived from the Leasing segment. Leasing revenue is generated from restaurants, retail outlets, office buildings, warehouses, and other resort activities.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: